{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:37:56Z","timestamp":1782286676072,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hubei Provincial Health Committee General Program","award":["WJ2023M004"],"award-info":[{"award-number":["WJ2023M004"]}]},{"name":"Beijing Medical Award Foundation Program","award":["YXJL-2023-0866-0329"],"award-info":[{"award-number":["YXJL-2023-0866-0329"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunoglobulin A vasculitis (IgAV) is the most common childhood vasculitis and can lead to immunoglobulin A vasculitis nephritis (IgAVN) in severe cases, potentially progressing to kidney failure in a subset of children. Safer and more effective treatments are needed to improve outcomes in these children. This study aimed to evaluate the efficacy and safety of telitacicept in the treatment of children with IgAV and IgAVN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-center, retrospective observational study of twenty four children with IgAV or IgAVN who received telitacicept treatment, and thirty matched children with IgAVN who only received conventional treatment were taken as the control group for children with IgAVN who received telitacicept treatment in acute phase. The treatment response was evaluated through urine protein, serum albumin, eGFR and serum immunoglobulin levels, and data was analyzed at telitacicept initiation and at 4, 12, 24 and 36 weeks after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of twenty four children (thirteen boys and eleven girls) with IgAV (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095) and IgAVN (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919, comprising ten acute and nine chronic cases) were enrolled. All children with IgAV experienced improvement of skin, joint, and gastrointestinal symptoms after telitacicept treatment, with no kidney involvement during follow-up. In children with IgAVN, the urinary protein-to-creatinine ratio (UPCR) significantly decreased at 36 weeks compared to baseline (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) in both acute and chronic groups, while estimated glomerular filtration rate (eGFR) remained stable (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). In addition, the dose of steroids administered during the treatment with telitacicept was significantly reduced, the acute IgAVN group exhibited significantly greater steroid reduction between weeks 4 and 24 compared with the controls group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Furthermore, serum immunoglobulin levels (IgA, IgG) significantly decreased 12 weeks after telitacicept treatment (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01), and no other adverse reactions observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Telitacicept appears to be a promising therapy for children with IgAV and IgAVN, effectively inducing proteinuria remission, improving systemic symptoms, and reducing the use of steroids, with favorable safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-025-01159-3","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:30:48Z","timestamp":1761042648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study"],"prefix":"10.1186","volume":"23","author":[{"given":"Xueqing","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9444-3464","authenticated-orcid":false,"given":"Liru","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"1","key":"1159_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","volume":"18","author":"RA Watts","year":"2022","unstructured":"Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022;18(1):22\u201334. https:\/\/doi.org\/10.1038\/s41584-021-00718-8.","journal-title":"Nat Rev Rheumatol"},{"issue":"9334","key":"1159_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/S0140-6736(02)09835-5","volume":"360","author":"J Ronkainen","year":"2002","unstructured":"Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Sch\u00f6nlein purpura: a retrospective cohort study. Lancet. 2002;360(9334):666\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(02)09835-5.","journal-title":"Lancet"},{"issue":"10","key":"1159_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2014.126","volume":"10","author":"JC Davin","year":"2014","unstructured":"Davin JC, Coppo R. Henoch-Sch\u00f6nlein purpura nephritis in children [J]. Nat Rev Nephrol. 2014;10(10):563\u201373. https:\/\/doi.org\/10.1038\/nrneph.2014.126.","journal-title":"Nat Rev Nephrol"},{"key":"1159_CR4","doi-asserted-by":"publisher","unstructured":"Bogdanovi\u0107 R. Henoch-Sch\u00f6nlein purpura nephritis in children: risk factors, prevention and treatment [J]. Acta Paediatr. 2009;98(12):1882\u20139. https:\/\/doi.org\/10.1111\/j.1651-2227.2009.01445.x","DOI":"10.1111\/j.1651-2227.2009.01445.x"},{"issue":"8788","key":"1159_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0140-6736(92)91341-5","volume":"339","author":"AR Goldstein","year":"1992","unstructured":"Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch-Sch\u00f6nlein nephritis [J]. Lancet (London England). 1992;339(8788):280\u20132. https:\/\/doi.org\/10.1016\/0140-6736(92)91341-5.","journal-title":"Lancet (London England)"},{"issue":"2","key":"1159_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/annrheumdis-2018-214142","volume":"78","author":"A Tracy","year":"2019","unstructured":"Tracy A, Subramanian A, Adderley NJ, et al. Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Sch\u00f6nlein purpura): a retrospective cohort study using routinely collected primary care data [J]. Ann Rheum Dis. 2019;78(2):261\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214142.","journal-title":"Ann Rheum Dis"},{"key":"1159_CR7","doi-asserted-by":"publisher","unstructured":"Jimenez A, Chen A, Lin JJ, South AM. Does MEST-C score predict outcomes in pediatric Henoch-Sch\u00f6nlein purpura nephritis? [J]. Pediatr Nephrol. 2019;34(12):2583\u20139. https:\/\/doi.org\/10.1007\/s00467-019-04327-2","DOI":"10.1007\/s00467-019-04327-2"},{"issue":"2","key":"1159_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","volume":"40","author":"M Vivarelli","year":"2025","unstructured":"Vivarelli M, Samuel S, Coppo R, et al. IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis[J]. Pediatr Nephrol. 2025;40(2):533\u201369. https:\/\/doi.org\/10.1007\/s00467-024-06502-6.","journal-title":"Pediatr Nephrol"},{"key":"1159_CR9","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. The KDIGO 2024 clinical practice guideline for the management of IgA nephropathy (IgAN) and IgA vasculitis (IgAV) (public review draft)[EB\/OL]. 2024 [cited 2025 Jun 8]. https:\/\/kdigo.org\/igan-igav-public-review-draft"},{"issue":"1","key":"1159_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/ki.2011.16","volume":"80","author":"K Kiryluk","year":"2011","unstructured":"Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Sch\u00f6nlein purpura nephritis. Kidney Int. 2011;80(1):79\u201387. https:\/\/doi.org\/10.1038\/ki.2011.16.","journal-title":"Kidney Int"},{"issue":"1","key":"1159_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","volume":"36","author":"E Samy","year":"2017","unstructured":"Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3\u201319. https:\/\/doi.org\/10.1080\/08830185.2016.1276903.","journal-title":"Int Rev Immunol"},{"issue":"1","key":"1159_CR12","doi-asserted-by":"publisher","first-page":"11510","DOI":"10.1038\/s41598-021-91055-z","volume":"11","author":"D Prieto-Pe\u00f1a","year":"2021","unstructured":"Prieto-Pe\u00f1a D, Genre F, Remuzgo-Mart\u00ednez S, et al. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. Sci Rep. 2021;11(1):11510. https:\/\/doi.org\/10.1038\/s41598-021-91055-z.","journal-title":"Sci Rep"},{"key":"1159_CR13","doi-asserted-by":"publisher","first-page":"103291","DOI":"10.1016\/j.jaut.2024.103291","volume":"148","author":"L Zeng","year":"2024","unstructured":"Zeng L, Yang K, Wu Y, Yu G, Yan Y, Hao M, Song T, Li Y, Chen J, Sun L. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases. J Autoimmun. 2024;148:103291. https:\/\/doi.org\/10.1016\/j.jaut.2024.103291.","journal-title":"J Autoimmun"},{"issue":"3","key":"1159_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2022","unstructured":"Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep. 2022;8(3):499\u2013506. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014.","journal-title":"Kidney Int Rep"},{"key":"1159_CR15","doi-asserted-by":"publisher","first-page":"114596","DOI":"10.1016\/j.intimp.2025.114596","volume":"154","author":"L Chen","year":"2025","unstructured":"Chen L, Teng Y, Ma Q, Liu W, Dong W, Wang R. Efficacy and safety of telitacicept in patients with class III-V lupus nephritis: A real-world retrospective cohort study. Int Immunopharmacol. 2025;154:114596. https:\/\/doi.org\/10.1016\/j.intimp.2025.114596.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1159_CR16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ekir.2024.11.1363","volume":"10","author":"J Liu","year":"2024","unstructured":"Liu J, Han X, Jiang X, et al. Efficacy and safety of telitacicept as an Add-On therapy for refractory Immunoglobulin A nephropathy or Immunoglobulin A vasculitis nephropathy in children. Kidney Int Rep. 2024;10(3):940\u20133. https:\/\/doi.org\/10.1016\/j.ekir.2024.11.1363.","journal-title":"Kidney Int Rep"},{"issue":"8","key":"1159_CR17","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00467-025-06769-3","volume":"40","author":"Y Jin","year":"2025","unstructured":"Jin Y, Zhu J, Sheng A, Lin Q, Zhao M, He X, Mao J, Fu H. Telitacicept as a BAFF\/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis. Pediatr Nephrol. 2025;40(8):2561\u20139. https:\/\/doi.org\/10.1007\/s00467-025-06769-3.","journal-title":"Pediatr Nephrol"},{"key":"1159_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-025-06709-1","author":"J Wang","year":"2025","unstructured":"Wang J, Cui J, Chen J, Liao Y, Yang M, Lin J, Yang X, Zhao B. Telitacicept use in children with IgA vasculitis nephritis: preliminary observations. Pediatr Nephrol. 2025. https:\/\/doi.org\/10.1007\/s00467-025-06709-1.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1159_CR19","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/ard.2009.116657","volume":"69","author":"S Ozen","year":"2010","unstructured":"Ozen S, Pistorio A, Iusan SM, et al. EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798\u2013806. https:\/\/doi.org\/10.1136\/ard.2009.116657.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1159_CR20","doi-asserted-by":"publisher","first-page":"e0167346","DOI":"10.1371\/journal.pone.0167346","volume":"11","author":"H Chan","year":"2016","unstructured":"Chan H, Tang YL, Lv XH, Zhang GF, Wang M, Yang HP, Li Q. Risk factors associated with renal involvement in childhood Henoch-Sch\u00f6nlein purpura: A Meta-Analysis. PLoS ONE. 2016;11(11):e0167346. https:\/\/doi.org\/10.1371\/journal.pone.0167346.","journal-title":"PLoS ONE"},{"issue":"8","key":"1159_CR21","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/art.1780330809","volume":"33","author":"JA Mills","year":"1990","unstructured":"Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, et al. The American college of rheumatology 1990 criteria for the classification of Henoch-Sch\u00f6nlein purpura. Arthritis Rheum. 1990;33(8):1114\u201321. https:\/\/doi.org\/10.1002\/art.1780330809.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1159_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/adc.2005.074641","volume":"90","author":"H Narchi","year":"2005","unstructured":"Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005;90(9):916\u201320. https:\/\/doi.org\/10.1136\/adc.2005.074641.","journal-title":"Arch Dis Child"},{"issue":"12","key":"1159_CR23","first-page":"911","volume":"47","author":"The Subspecialty Group of Nephrolog","year":"2009","unstructured":"The Subspecialty Group of Nephrology, Society of Pediatrics, Chinese Medical Association. Evidence-based guidelines on diagnosis and treatment of childhood common renal diseases (II): evidence-based guideline on diagnosis and treatment of Henoch-Schonlein purpura nephritis. Chin J Pediatr. 2009;47(12):911\u20133.","journal-title":"Chin J Pediatr"},{"key":"1159_CR24","doi-asserted-by":"publisher","unstructured":"Chap. 11: Henoch-Sch\u00f6nlein purpura nephritis. Kidney Int Suppl (2011). 2012;2(2):218\u2013220. https:\/\/doi.org\/10.1038\/kisup.2012.24","DOI":"10.1038\/kisup.2012.24"},{"issue":"12","key":"1159_CR25","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1007\/s10067-023-06781-8","volume":"42","author":"CEC Williams","year":"2023","unstructured":"Williams CEC, Lamond M, Marro J, Chetwynd AJ, Oni L. A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP). Clin Rheumatol. 2023;42(12):3189\u2013200. https:\/\/doi.org\/10.1007\/s10067-023-06781-8.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1159_CR26","first-page":"195","volume":"124","author":"R Fenoglio","year":"2020","unstructured":"Fenoglio R, Sciascia S, Naretto C, De Simone E, Del Vecchio G, Ferro M, Quattrocchio G, Roccatello D. Rituximab in severe immunoglobulin-A vasculitis (Henoch-Sch\u00f6nlein) with aggressive nephritis. Clin Exp Rheumatol. 2020;124(2):195\u2013200.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1159_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s40001-023-01320-2","volume":"28","author":"L Wu","year":"2023","unstructured":"Wu L, Du X, Lu X. Role of telitacicept in the treatment of IgA nephropathy. Eur J Med Res. 2023;28(1):369. https:\/\/doi.org\/10.1186\/s40001-023-01320-2.","journal-title":"Eur J Med Res"},{"issue":"4","key":"1159_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(4):475\u201387. https:\/\/doi.org\/10.1136\/ard-2023-224854.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1159_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z, Huang C, Huang W. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus. 2023;32(1):94\u2013100. https:\/\/doi.org\/10.1177\/09612033221141253.","journal-title":"Lupus"},{"issue":"1","key":"1159_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13000-019-0818-0","volume":"14","author":"X Huang","year":"2019","unstructured":"Huang X, Ma L, Ren P, et al. Updated Oxford classification and the international study of kidney disease in children classification: application in predicting outcome of Henoch-Sch\u00f6nlein purpura nephritis. Diagn Pathol. 2019;14(1):40. https:\/\/doi.org\/10.1186\/s13000-019-0818-0.","journal-title":"Diagn Pathol"},{"issue":"6","key":"1159_CR31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00467-010-1444-y","volume":"25","author":"S Edstr\u00f6m Halling","year":"2010","unstructured":"Edstr\u00f6m Halling S, S\u00f6derberg MP, Berg UB. Predictors of outcome in Henoch-Sch\u00f6nlein nephritis. Pediatr Nephrol. 2010;25(6):1101\u20138. https:\/\/doi.org\/10.1007\/s00467-010-1444-y.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"1159_CR32","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/modpathol.2013.222","volume":"27","author":"CH Kim","year":"2014","unstructured":"Kim CH, Lim BJ, Bae YS, et al. Using the Oxford classification of IgA nephropathy to predict long-term outcomes of Henoch-Sch\u00f6nlein purpura nephritis in adults. Mod Pathol. 2014;27(7):972\u201382. https:\/\/doi.org\/10.1038\/modpathol.2013.222.","journal-title":"Mod Pathol"},{"issue":"1","key":"1159_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12882-020-1691-5","volume":"21","author":"D Yun","year":"2020","unstructured":"Yun D, Kim DK, Oh KH, et al. MEST-C pathological score and long-term outcomes of child and adult patients with Henoch-Sch\u00f6nlein purpura nephritis. BMC Nephrol. 2020;21(1):33. https:\/\/doi.org\/10.1186\/s12882-020-1691-5.","journal-title":"BMC Nephrol"},{"issue":"2","key":"1159_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40620-017-0457-z","volume":"31","author":"K Xu","year":"2018","unstructured":"Xu K, Zhang L, Ding J, et al. Value of the Oxford classification of IgA nephropathy in children with Henoch-Sch\u00f6nlein purpura nephritis. J Nephrol. 2018;31(2):279\u201386. https:\/\/doi.org\/10.1007\/s40620-017-0457-z.","journal-title":"J Nephrol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01159-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:04:29Z","timestamp":1761087869000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01159-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1159"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01159-3","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (TJ-IRB202412090), all methods were carried out in accordance with relevant guidelines and regulations. Informed consents were obtained from the patients parents\/legal guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients parents\/legal guardian for publication of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}